Krebs Biochemicals & Industries Limited (KREBSBIO.BO)
INR 98.95
(-0.3%)
INR 98.95
(-0.3%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.93 Billion INR | -15.3% |
| 2022 | 2.28 Billion INR | 21.41% |
| 2021 | 1.88 Billion INR | 49.12% |
| 2020 | 1.26 Billion INR | 55.32% |
| 2019 | 812.12 Million INR | -13.71% |
| 2018 | 941.12 Million INR | 2.43% |
| 2017 | 918.8 Million INR | 16.63% |
| 2016 | 787.82 Million INR | 157.72% |
| 2015 | 305.69 Million INR | 42.36% |
| 2014 | 214.72 Million INR | 0.0% |
| 2011 | 799.26 Million INR | -7.04% |
| 2010 | 859.82 Million INR | -0.85% |
| 2009 | 867.23 Million INR | 4.89% |
| 2008 | 826.76 Million INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 FY | 1.93 Billion INR | -15.3% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 1.93 Billion INR | 0.0% |
| 2023 Q2 | 1.87 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 2.28 Billion INR | 21.41% |
| 2022 Q2 | 1.73 Billion INR | 0.0% |
| 2022 Q4 | 2.28 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 1.22 Billion INR | 0.0% |
| 2021 Q4 | 1.88 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 1.88 Billion INR | 49.12% |
| 2020 FY | 1.26 Billion INR | 55.32% |
| 2020 Q4 | 1.26 Billion INR | 0.0% |
| 2020 Q2 | 819.14 Million INR | 0.0% |
| 2019 Q4 | 812.12 Million INR | 0.0% |
| 2019 Q2 | 512.27 Million INR | 0.0% |
| 2019 FY | 812.12 Million INR | -13.71% |
| 2018 Q4 | 941.12 Million INR | 0.0% |
| 2018 Q2 | 509.5 Million INR | 0.0% |
| 2018 FY | 941.12 Million INR | 2.43% |
| 2017 Q4 | 516.61 Million INR | 0.0% |
| 2017 Q2 | 514.44 Million INR | 0.0% |
| 2017 FY | 918.8 Million INR | 16.63% |
| 2016 FY | 787.82 Million INR | 157.72% |
| 2016 Q2 | 794.24 Million INR | 0.0% |
| 2016 Q4 | 427.87 Million INR | 0.0% |
| 2015 FY | 305.69 Million INR | 42.36% |
| 2015 Q4 | 305.69 Million INR | 0.0% |
| 2015 Q2 | 656.47 Million INR | 0.0% |
| 2014 FY | 214.72 Million INR | 0.0% |
| 2013 Q3 | 270.78 Million INR | 0.0% |
| 2012 Q2 | 874.96 Million INR | 0.0% |
| 2011 FY | 799.26 Million INR | -7.04% |
| 2011 Q4 | 799.26 Million INR | 0.0% |
| 2010 FY | 859.82 Million INR | -0.85% |
| 2009 FY | 867.23 Million INR | 4.89% |
| 2008 FY | 826.76 Million INR | 0.0% |
| 2008 Q4 | 826.76 Million INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Ajanta Pharma Limited | 352.8 Million INR | -448.27% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -11091.894% |
| Sigachi Industries Limited | 1.43 Billion INR | -35.216% |
| Bal Pharma Limited | 1.39 Billion INR | -38.512% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -1063.724% |
| Medico Remedies Limited | 80.5 Million INR | -2302.732% |
| Lasa Supergenerics Limited | 220.76 Million INR | -776.19% |
| Venus Remedies Limited | 413.3 Million INR | -368.012% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | -216.32% |
| Alpa Laboratories Limited | 52.46 Million INR | -3586.829% |
| Nectar Lifesciences Limited | 6.35 Billion INR | 69.564% |
| Shilpa Medicare Limited | 9.37 Billion INR | 79.365% |
| Aarti Drugs Limited | 5.64 Billion INR | 65.72% |
| Lupin Limited | 29.21 Billion INR | 93.38% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 97.09% |
| Zydus Lifesciences Limited | 8.04 Billion INR | 75.948% |
| Windlas Biotech Limited | 36.41 Million INR | -5212.538% |
| Suven Life Sciences Limited | 7.09 Million INR | -27155.108% |
| Eris Lifesciences Limited | 27.81 Billion INR | 93.045% |
| Valiant Laboratories Limited | 767.08 Million INR | -152.162% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | 48.782% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | 80.877% |
| Ipca Laboratories Limited | 14.38 Billion INR | 86.552% |
| Bliss GVS Pharma Limited | 998.4 Million INR | -93.739% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 94.091% |
| Bajaj HealthCare Limited | 3.32 Billion INR | 41.882% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Mankind Pharma Limited | 2.07 Billion INR | 6.634% |
| Laurus Labs Limited | 25.77 Billion INR | 92.495% |
| Piramal Pharma Limited | 47.1 Billion INR | 95.893% |
| Syncom Formulations (India) Limited | 724.86 Million INR | -166.849% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 95.191% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | 62.306% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 84.286% |
| Unichem Laboratories Limited | 2.47 Billion INR | 21.851% |
| Sequent Scientific Limited | 4.87 Billion INR | 60.338% |
| Novartis India Limited | 69.7 Million INR | -2675.172% |
| Wanbury Limited | 1.16 Billion INR | -66.056% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | -197.6% |
| Wockhardt Limited | 23.56 Billion INR | 91.79% |
| Themis Medicare Limited | 957.92 Million INR | -101.926% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -2063.399% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 94.721% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -1028.0% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 90.338% |
| Divi's Laboratories Limited | 30 Million INR | -6347.65% |
| NATCO Pharma Limited | 3.71 Billion INR | 47.891% |
| Gufic Biosciences Limited | 3.32 Billion INR | 41.898% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | -490.444% |
| Ind-Swift Limited | 10.13 Billion INR | 80.924% |
| Procter & Gamble Health Limited | 95.6 Million INR | -1923.321% |
| FDC Limited | 205.18 Million INR | -842.708% |
| Granules India Limited | 13.15 Billion INR | 85.291% |
| Medicamen Biotech Limited | 308.17 Million INR | -527.667% |
| Alkem Laboratories Limited | 14.18 Billion INR | 86.363% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -4106.635% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -43971.429% |
| Brooks Laboratories Limited | 56.41 Million INR | -3328.446% |
| Megasoft Limited | 1.47 Billion INR | -31.543% |
| ZIM Laboratories Limited | 1.08 Billion INR | -77.745% |
| Strides Pharma Science Limited | 25.16 Billion INR | 92.315% |
| Neuland Laboratories Limited | 953.89 Million INR | -102.778% |
| Morepen Laboratories Limited | 289.99 Million INR | -567.017% |
| Hikal Limited | 8.17 Billion INR | 76.341% |
| Indoco Remedies Limited | 6.71 Billion INR | 71.214% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | 32.189% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | -511.219% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | -96.39% |
| Hester Biosciences Limited | 2.44 Billion INR | 20.848% |